MASH Clinical Trials

Nov 09 2025
Convention Center: Hall A (General Session), Concourse Level
2:00 PM - 3:30 PM

World Class Speakers

Naim Alkhouri, MD, FAASLD
Abstract Presenter

Naim Alkhouri, MD, FAASLD

Summit Clinical Research
Mazen Noureddin
Abstract Presenter

Mazen Noureddin

Houston Research Institute and Houston Methodist Hospital
Jörn M Schattenberg, MD
Abstract Presenter

Jörn M Schattenberg, MD

Saarland University Medical Center Homburg
Mary E. Rinella, MD, FAASLD
Moderator

Mary E. Rinella, MD, FAASLD

The University of Chicago
Jörn M Schattenberg, MD
Moderator

Jörn M Schattenberg, MD

Saarland University Medical Center Homburg

Description

Researchers in this abstract parallel session will share the results of recent clinical trials in MASH.

Journey Maps

Presentations

2:15 PM - 2:30 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

A randomized, placebo-controlled, phase 2 study of the safety and efficacy of combination treatment with semaglutide, cilofexor and firsocostat in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (WAYFIND)

Naim Alkhouri, MD, FAASLD , Abstract Presenter
MASLD
2:30 PM - 2:45 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

Safety and Efficacy of Cotadutide, a dual GLP-1 and Glucagon receptor agonist in Adults with Non-cirrhotic Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis: Final results from a Phase IIb Randomized, Placebo-controlled,

Mazen Noureddin , Abstract Presenter
MASLD
2:45 PM - 3:00 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

Efruxifermin improved markers of portal hypertension as evaluated by Baveno VII criteria in compensated cirrhosis due to MASH: results from a 96-week, placebo-controlled, phase 2b trial (SYMMETRY)

Mazen Noureddin , Abstract Presenter
MASLD
3:15 PM - 3:30 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

Improvement in Liver Fat Content and MASH Biomarkers with Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist in Subjects with MAFLD: A Phase 1a/2b Study 

Jörn M Schattenberg, MD , Abstract Presenter
MASLD

Objectives

  • Describe new efficacy and safety data from recent MASH clinical trials, highlighting potential therapeutic advances.
  • Analyze key secondary outcomes and subgroup findings to identify implications for patient selection and the effect on clinical trials.